Researchers have shown that inhibiting VEGF and Ang–2 jointly results in tumor necrosis, vascular regression, intra-tumoral phagocyte antigen presentation, and a reduction in breast cancer-brain metastases (67, 68). This evidence concerns the gene VEGFA and neoplasm.